Bohem

Piramal Pharma: In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal

by

Nandini Piramal, Chairperson, Piramal Pharma, says “for FY25, we are actually guiding an early teens absolute improvement in revenue and early teens margin growth as well. So, that is what I can say for FY26. In three to five years, we can see 22- 25% EBITDA growth margins.”This time your margins were close to like … Read more